118 related articles for article (PubMed ID: 22540538)
1. Method for predicting human intestinal first-pass metabolism of UGT substrate compounds.
Furukawa T; Yamano K; Naritomi Y; Tanaka K; Terashita S; Teramura T
Xenobiotica; 2012 Oct; 42(10):980-8. PubMed ID: 22540538
[TBL] [Abstract][Full Text] [Related]
2. Quantitative prediction of human intestinal glucuronidation effects on intestinal availability of UDP-glucuronosyltransferase substrates using in vitro data.
Nakamori F; Naritomi Y; Hosoya K; Moriguchi H; Tetsuka K; Furukawa T; Kadono K; Yamano K; Terashita S; Teramura T
Drug Metab Dispos; 2012 Sep; 40(9):1771-7. PubMed ID: 22685216
[TBL] [Abstract][Full Text] [Related]
3. Quantitative prediction of intestinal glucuronidation of drugs in rats using in vitro metabolic clearance data.
Furukawa T; Nakamori F; Tetsuka K; Naritomi Y; Moriguchi H; Yamano K; Terashita S; Teramura T
Drug Metab Pharmacokinet; 2012; 27(2):171-80. PubMed ID: 21970858
[TBL] [Abstract][Full Text] [Related]
4. Assessment of UDP-glucuronosyltransferase catalyzed formation of Picroside II glucuronide in microsomes of different species and recombinant UGTs.
Li T; Zheng Y; Fu F; Ji H; Chen X; Zhao Y; Zhao D; Li N; Zhang L
Xenobiotica; 2011 Jul; 41(7):530-7. PubMed ID: 21524190
[TBL] [Abstract][Full Text] [Related]
5. Characterization of in vitro glucuronidation clearance of a range of drugs in human kidney microsomes: comparison with liver and intestinal glucuronidation and impact of albumin.
Gill KL; Houston JB; Galetin A
Drug Metab Dispos; 2012 Apr; 40(4):825-35. PubMed ID: 22275465
[TBL] [Abstract][Full Text] [Related]
6. Raloxifene glucuronidation in liver and intestinal microsomes of humans and monkeys: contribution of UGT1A1, UGT1A8 and UGT1A9.
Kishi N; Takasuka A; Kokawa Y; Isobe T; Taguchi M; Shigeyama M; Murata M; Suno M; Hanioka N
Xenobiotica; 2016; 46(4):289-95. PubMed ID: 26247833
[TBL] [Abstract][Full Text] [Related]
7. Prediction of the intestinal first-pass metabolism of CYP3A and UGT substrates in humans from in vitro data.
Nishimuta H; Sato K; Yabuki M; Komuro S
Drug Metab Pharmacokinet; 2011; 26(6):592-601. PubMed ID: 21878741
[TBL] [Abstract][Full Text] [Related]
8. Regioselective glucuronidation of denopamine: marked species differences and identification of human udp-glucuronosyltransferase isoform.
Kaji H; Kume T
Drug Metab Dispos; 2005 Mar; 33(3):403-12. PubMed ID: 15608137
[TBL] [Abstract][Full Text] [Related]
9. Metabolism of the c-Fos/activator protein-1 inhibitor T-5224 by multiple human UDP-glucuronosyltransferase isoforms.
Uchihashi S; Fukumoto H; Onoda M; Hayakawa H; Ikushiro S; Sakaki T
Drug Metab Dispos; 2011 May; 39(5):803-13. PubMed ID: 21346002
[TBL] [Abstract][Full Text] [Related]
10. Prediction of drug clearance by glucuronidation from in vitro data: use of combined cytochrome P450 and UDP-glucuronosyltransferase cofactors in alamethicin-activated human liver microsomes.
Kilford PJ; Stringer R; Sohal B; Houston JB; Galetin A
Drug Metab Dispos; 2009 Jan; 37(1):82-9. PubMed ID: 18832476
[TBL] [Abstract][Full Text] [Related]
11. Impact of intestinal glucuronidation on the pharmacokinetics of raloxifene.
Kosaka K; Sakai N; Endo Y; Fukuhara Y; Tsuda-Tsukimoto M; Ohtsuka T; Kino I; Tanimoto T; Takeba N; Takahashi M; Kume T
Drug Metab Dispos; 2011 Sep; 39(9):1495-502. PubMed ID: 21646435
[TBL] [Abstract][Full Text] [Related]
12. Intestinal glucuronidation metabolism may have a greater impact on oral bioavailability than hepatic glucuronidation metabolism in humans: a study with raloxifene, substrate for UGT1A1, 1A8, 1A9, and 1A10.
Mizuma T
Int J Pharm; 2009 Aug; 378(1-2):140-1. PubMed ID: 19486934
[TBL] [Abstract][Full Text] [Related]
13. Relative importance of intestinal and hepatic glucuronidation-impact on the prediction of drug clearance.
Cubitt HE; Houston JB; Galetin A
Pharm Res; 2009 May; 26(5):1073-83. PubMed ID: 19184618
[TBL] [Abstract][Full Text] [Related]
14. Human pharmacokinetic prediction of UDP-glucuronosyltransferase substrates with an animal scale-up approach.
Deguchi T; Watanabe N; Kurihara A; Igeta K; Ikenaga H; Fusegawa K; Suzuki N; Murata S; Hirouchi M; Furuta Y; Iwasaki M; Okazaki O; Izumi T
Drug Metab Dispos; 2011 May; 39(5):820-9. PubMed ID: 21282406
[TBL] [Abstract][Full Text] [Related]
15. Prediction of hepatic and intestinal glucuronidation using in vitro-in vivo extrapolation.
Naritomi Y; Nakamori F; Furukawa T; Tabata K
Drug Metab Pharmacokinet; 2015 Feb; 30(1):21-9. PubMed ID: 25760528
[TBL] [Abstract][Full Text] [Related]
16. Species differences in intestinal glucuronidation activities between humans, rats, dogs and monkeys.
Furukawa T; Naritomi Y; Tetsuka K; Nakamori F; Moriguchi H; Yamano K; Terashita S; Tabata K; Teramura T
Xenobiotica; 2014 Mar; 44(3):205-16. PubMed ID: 23962030
[TBL] [Abstract][Full Text] [Related]
17. Glucuronidation of fenamates: kinetic studies using human kidney cortical microsomes and recombinant UDP-glucuronosyltransferase (UGT) 1A9 and 2B7.
Gaganis P; Miners JO; Knights KM
Biochem Pharmacol; 2007 May; 73(10):1683-91. PubMed ID: 17343829
[TBL] [Abstract][Full Text] [Related]
18. Glucuronidation of zearalenone, zeranol and four metabolites in vitro: formation of glucuronides by various microsomes and human UDP-glucuronosyltransferase isoforms.
Pfeiffer E; Hildebrand A; Mikula H; Metzler M
Mol Nutr Food Res; 2010 Oct; 54(10):1468-76. PubMed ID: 20397195
[TBL] [Abstract][Full Text] [Related]
19. Glucuronidation of edaravone by human liver and kidney microsomes: biphasic kinetics and identification of UGT1A9 as the major UDP-glucuronosyltransferase isoform.
Ma L; Sun J; Peng Y; Zhang R; Shao F; Hu X; Zhu J; Wang X; Cheng X; Zhu Y; Wan P; Feng D; Wu H; Wang G
Drug Metab Dispos; 2012 Apr; 40(4):734-41. PubMed ID: 22238289
[TBL] [Abstract][Full Text] [Related]
20. Stereoselective glucuronidation of carvedilol in human liver and intestinal microsomes.
Hanioka N; Tanaka S; Moriguchi Y; Narimatsu S
Pharmacology; 2012; 90(3-4):117-24. PubMed ID: 22814440
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
